Table 3 Dysregulation of miR-16-5p or its partners in clinical samples (NB: Neuroblastoma, FAM: fetal adrenal medulla, ANCTs: adjacent non-cancerous tissues, OS: Overall survival, TNM: tumor-node‐metastasis, ccRCC: clear cell renal cell carcinoma)
From: A review on the role of mir-16-5p in the carcinogenesis
Tumor type | samples | Expression of miR-16-5p or other genes (Tumor vs. Normal) | Kaplan-Meier analysis (impact of miR-16-5p dysregulation) | Association of expression of miR-16-5p or expression of other genes with clinicopathologic characteristics | Method by which RNA was detected | Reference |
|---|---|---|---|---|---|---|
Neuroblastoma | R2 database, containing 105 NB patients | Down | [7] | |||
50 pairs of tumor tissues and FAM tissues | Upregulation in circ-CUX1 (which sponges miR-16-5p) | Lower OS | Upregulation in circ-CUX1 was correlated with advanced TNM stage, low differentiation grade and lymph node metastasis. | [8] | ||
Osteosarcoma | 40 pairs of tumor tissues and ANCTs | Down | Lower OS | SYBR® Premix Ex TaqTM Kit | [9] | |
51 pairs of tumor tissues and ANCTs | Upregulation in LINC00662 (which sponges miR-16-5p) | Lower OS | Upregulation in LINC00662 was correlated with distant metastasis, TNM stage, and tumor size. | [23] | ||
30 pairs of tumor tissues and ANCTs | Upregulation in hsa_circ_0005721 (which sponges miR-16-5p) | SYBR®Premix Ex Taq™ | [24] | |||
Hepatocellular carcinoma | 137 pairs of tumor tissues and ANCTs | Upregulation in AGAP2-AS1 (which sponges miR-16-5p) Downregulation in miR-16-5p | Upregulation in LINC00662 was correlated with large tumor size, metastasis, recurrence and high histological grade tissues | - | [11] | |
100 pairs of tumor tissues and ANCTs | Downregulation in miR-16-5p | SYBR PrimeScriptTM RT-PCR Kit | [12] | |||
60 pairs of tumor tissues and ANCTs | Upregulation in SNHG22 (which suppresses transcription of miR-16-5p) | Lower OS | SYBR Green PCR kit | [14] | ||
Cervical cancer | 63 pairs of tumor tissues and ANCTs | Upregulation in CARM1 (a target of miR-16-5p) Downregulation in miR-16-5p | Upregulation in CARM1 was correlated with higher clinical staging and poorer tumor differentiation | SYBR Green PCR kit | [15] | |
Gliomas | 72 pairs of tumor tissues and ANCTs | Downregulation in miR-16-5p | SYBR Green I fluorescence method | [17] | ||
GEO and TCGA databases | Upregulation in ANLN (a target of miR-16-5p) | Lower OS | [18] | |||
40 pairs of tumor tissues and ANCTs | Downregulation in miR-16-5p | SYBR Green kit | [19] | |||
22 pairs of tumor tissues and ANCTs | Upregulation in ATXN8OS (which sponges miR-16-5p) | SYBR® Premix Ex TaqTM reagent | [20] | |||
Gliomas | 79 patients with astrocytic gliomas and 9 non-neoplastic brain samples | Downregulation in miR-16-5p | TaqMan probe | [21] | ||
Chordoma | 12 chordoma tissues and 12 nucleus pulposus tissues 10 chordoma tissues and 5 nucleus pulposus tissues | Downregulation in miR-16-5p | SYBR-Green PCR Master Mix | [27] | ||
30 pairs of tumor tissues and ANCTs | Upregulation in LINC00662 (which sponges miR-16-5p) | RT2 SYBR Green FAST Mastermix or miScript SYBR Green PCR Kit | [28] | |||
Gastric cancer | 54 pairs of tumor tissues and ANCTs TCGA dataset | Downregulation in miR-16-5p | One-Step TB Green TM PrimeScript TM RT-PCR kit | [31] | ||
53 pairs of tumor tissues and ANCTs | Upregulation in Linc00210 (which sponges miR-16-5p) | Upregulation in LINC00473 was correlated with a higher risk of lymphatic metastasis, a higher incidence of vascular cancer embolus, and advanced TNM stage. | TB Premix Ex Taq | [32] | ||
Lung cancer | 40 pairs of tumor tissues and ANCTs | Upregulation in Linc00210 (which sponges miR-16-5p) | SYBR Premix Ex Taq II and Perfect Real Time | [34] | ||
31 pairs of tumor tissues and ANCTs | Upregulation in XIST (which sponges miR-16-5p) | SYBR Green Master Mix | [35] | |||
Colorectal cancer | 72 pairs of tumor tissues and ANCTs | Upregulation in PVT1 (which sponges miR-16-5p) | Lower OS | Upregulation in PVT1 was significantly correlated with lymph node metastasis, distant metastasis, and TNM (tumor, node, metastasis) stage | SYBR Green | [36] |
42 pairs of tumor tissues and ANCTs | Upregulation in ALDH1A3 (a target of miR-16-5p) | Lower OS | [37] | |||
GEO database: GSE75970, GSE74602, GSE89076, and GSE10950 | Upregulation in ITGA2 (a target of miR-16-5p) | [38] | ||||
Chronic lymphocytic leukemia | 224 CLL cases and 224 matched controls | miR-16-5p levels were unrelated to CLL risk. | TaqMan probes | [49] | ||
Chondrosarcoma | 9 human chondrosarcoma tissues and 9 normal cartilage | Downregulation in miR-16-5p | [42] | |||
Giant cell tumor of bone | 17 GCT tissue and 4 cancellous bone as controls | Downregulation in miR-16-5p | iTaq™ Universal SYBR Green Supermix | [43] | ||
Ovarian cancer | 142 ovarian cancer patients, and 97 healthy controls | Upregulation in miR-16-5p | No correlation between the gene expression levels, and the survival time | [50] | ||
Renal cell carcinoma | 25 patients with ccRCC | Upregulation in PVT1 (which sponges miR-16-5p) | Upregulation in PVT1 was correlated with TNM stage, Fuhrman grade, lymph node metastasis and tumor size. | SYBR Green | [45] |